C
Cullinan Therapeutics, Inc. (CGEM)
NMS – Real vaqt narxi. Valyuta: USD
16.15
+1.42 (9.64%)
Yopilishda: May 12, 2026, 4:00 PM EDT
16.14
-0.01 (-0.06%)
Bozordan keyin: May 12, 2026, 7:58 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
16.15
+1.42 (9.64%)
Yopilishda: May 12, 2026, 4:00 PM EDT
16.14
-0.01 (-0.06%)
Bozordan keyin: May 12, 2026, 7:58 PM EDT
Cullinan Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda autoimmun kasalliklar va saraton uchun terapiyalarni ishlab chiqadi. Kompaniya autoimmun kasalliklar uchun CD19xCD3 bispesifik T-hujayra faollashtiruvchi CLN-978, autoimmun kasalliklar uchun BCMAxCD3 bispesifik T-hujayra faollashtiruvchi Velinotamig va qaytalangan va refrakter o'tkir miyeloid leykemiya yoki miyelodisplastik sindrom bilan kasallangan bemorlarda birinchi bosqich klinik sinovlarda bo'lgan FLT3xCD3 bispesifik T-hujayra faollashtiruvchi CLN-049ni ishlab chiqish bilan shug'ullanadi. Kompaniya, shuningdek, EGFR ex20ins kichik hujayrali o'pka saratoni bilan kasallangan bemorlarda REZILIENT1 klinik sinovining 2b bosqichida og'iz orqali qabul qilinadigan, kichik molekulali, qaytarilmas epidermal o'sish omili retseptorlari ingibitori bo'lgan Zipalertinibni ishlab chiqmoqda. Kompaniya Velinotamigni ishlab chiqish va tijoratlashtirish uchun Chongqing Genrix Biopharmaceutical Co., Ltd bilan litsenziya shartnomasiga; Zipalertinibni ishlab chiqish uchun Taiho Pharmaceutical Co., Ltd bilan qo'shma ishlab chiqish shartnomasiga; va antitelalarni aniqlash va/yoki optimallashtirish uchun Adimab, LLC bilan hamkorlik shartnomasiga ega. Kompaniya ilgari Cullinan Oncology, Inc. nomi bilan tanilgan va 2024-yil aprel oyida Cullinan Therapeutics, Inc. nomini olgan. Cullinan Therapeutics, Inc. 2016-yilda tashkil etilgan va shtab-kvartirasi Kembrij, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Corinne Savill Ph.D. | Chief Business Officer |
| Dr. Jeffrey Jones M.B.A., M.D., M.P.H. | Chief Medical Officer |
| Dr. Jennifer Michaelson Ph.D. | Chief Scientific Officer |
| Dr. Patrick A. Baeuerle Ph.D. | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board |
| Mr. Nadim Ahmed M.S. | President, CEO & Director |
| Mr. Steve Andre | Chief Human Resources Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | cgem-20260507.htm |
| 2026-05-07 | 10-Q | cgem-20260331.htm |
| 2026-04-28 | S-3ASR | d587157ds3asr.htm |
| 2026-04-28 | DEFA14A | 2025_defa14a_filing.htm |
| 2026-04-28 | DEF 14A | cgem-20260427.htm |
| 2026-03-10 | S-8 | cgem-20260310.htm |
| 2026-01-08 | 8-K | cgem-20260108.htm |
| 2025-12-08 | 8-K | cgem-20251208.htm |
| 2025-11-21 | 8-K | cgem-20251118.htm |
| 2025-11-06 | 8-K | cgem-20251106.htm |
| Ms. Jacquelyn L. Sumer J.D. | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary |
| Ms. Mary Kay Fenton CPA | Chief Financial Officer |
| Ms. Rose Weldon | Senior Vice President of Corporate Affairs |
| Nicholas Smith | Head of Investor Relations |